. A multi-investigator, multi-center plan is proposed to develop gene-based retinal therapies for LCA- ciliopathies using the dog NPHP5 model. A subgroup of these human ciliopathies show early onset and profound congenital retinal and visual malfunction that results from abnormally developed photoreceptors (PR) that subsequently degenerate. The proposal builds on success achieved in the current grant period in moving RPGR-XLRP to a clinical trial, and recent studies in the NPHP5 model showing that a scAAV2/8- based viral vector, together with the human GRK1 promoter and human full-length NPHP5 cDNA, rescues ERG rod and cone function, and vision, for at least 1 year, but that PRs continue to degenerate, albeit at a much slower rate. This vector now serves as the benchmark test vector to assess treatment paradigms to optimize PR targeting, infectivity and therapeutic transgene expression that will result in permanent disease correction. The proposal will evaluate gene therapy in dogs having this aggressive and severe LCA- ciliopathy, and is divided into three aims that will: 1- establish the benchmark dose and disease stage treatment efficacy of the test vector; 2- select the lead vector pseudotype and promoter with optimized transduction efficiency, and efficacy in targeting different PR disease stages; 3- facilitate translational studies by defining the natural history of the disease in dogs and patients, the effect of treatment in dogs, and determining the degree of PR/retinal disease still amenable to treatment. While the test platform is the NPHP5-LCA dog model, the therapeutic questions addressed apply broadly to other LCA-ciliopathies. Four coordinated groups [a.k.a. modules (M)], are described that take advantage of the special expertise of each group to create a complementary and focused approach to the proposed translational studies. M1 (Large Animal Experimental) will produce the dog models, and provide infrastructure resources for the work; M2 (Large Animal Therapy) will carry out therapy studies and develop measures for outcome assessment; M3 (Non-invasive Patient and Dog Studies) will establish functional and structural disease features in the patients and model, and evaluate success of therapies in dogs using non-invasive outcome measures that correlate with ex vivo morphologic studies; M4 (Molecular Therapeutic Development) will provide therapeutic vectors. The research studies described in this proposal represents a continuation of a longstanding collaboration between the module scientists that already has brought retinal gene therapy for the treatment of patients with RPE65-LCA (Phase I clinical trial), and CNGB3-achromatopsia and RPGR-XLRP (both in final preparations for clinical trials). The University of Pennsylvania leads this collaboration with the University of Florida.
Leber congenital amaurosis (LCA)-ciliopathies represents a group of retinal diseases with profound congenital retinal and visual malfunction that results from abnormally developed PRs that subsequently degenerate. A large subgroup of diseases is caused by defects in genes/proteins expressed in the photoreceptor sensory cilium. Using the NPHP5 canine LCA- ciliopathy model, we will exploit a viral vector already proven effective in arresting the disease, to optimize treatments to permanently restore function and preserve structure at patient relevant disease stages.
Showing the most recent 10 out of 73 publications
